The present study introduces a novel therapeutic approach for ulcerative colitis (UC) utilizing American ginseng vesicles encapsulated within a hyaluronic acid (HA) hydrogel matrix. UC, a prevalent form of inflammatory bowel disease, is characterized by chronic inflammation of the colonic mucosa, leading to significant morbidity and compromised quality of life. Existing therapeutic modalities such as 5-Aminosalicylic acid (5-ASA) are associated with substantial side effects and a high recurrence rate. Thus, there is an unmet need for alternative treatments that offer enhanced efficacy with reduced adverse effects. Leveraging the anti-inflammatory properties of American ginseng vesicles HA -hydrogels of HA hydrogel (5-ASA + ANPs@HA), this study presents a targeted drug delivery system designed to provide localized therapy for UC. We synthesized the hydrogel matrix by HA and 1,4-butanediol diglycidyl ether (BDDE) at concentrations of 1 % NaOH and 0.8 %, v/v, respectively. The water content of the hydrogel was about 80 % to 90 %, and 82 % of Rb1 was released in 61 min. Our results demonstrate a significant reduction in disease symptoms, a substantial decrease in pro-inflammatory cytokines, and marked enhancement in mucosal healing following treatment with the 5-ASA + ANPs@HA. Collectively, these results suggest that the 5-ASA + ANPs@HA represents a promising therapeutic strategy for UC, warranting further investigation for clinical application.
Keywords: American ginseng; Drug delivery system; Hyaluronic acid; Inflammatory bowel disease; Ulcerative colitis.
Copyright © 2024 Elsevier B.V. All rights reserved.